Biofortuna (Deeside UK), a specialist contract development and manufacturing partner to the IVD and point of care testing sectors, has more than doubled its manufacturing capacity following its relocation to new state-of-the-art facilities in Deeside, North Wales.
The purpose-built facilities have been designed by the Company to provide the most efficient and modern manufacturing laboratories from which to meet the evolving needs of the world’s leading IVD and point of care businesses.
“This multi-million-pound investment demonstrates our ambition and commitment to become the sectors’ leading support specialist, helping our customers to accelerate their diagnostic development programmes from concept to commercialisation,” said Dr Nick Ash, Biofortuna Chief Executive Officer.
The new premises provide 450m³ of class-leading, humidity controlled clean room environment for formulation, dispensing, manufacturing and analysis of more than 10 million reactions per week.
“This facilities will position Biofortuna as one of the leading outsourced providers of genomic services, custom assay development and contract manufacturing. It has been designed to expand our turn-key capabilities and provide our customers with a scalable resource to develop and manufacture their assays, particularly in the point of care and de-centralised IVD testing space,” added Paul Williams, Head of Sales.
Biofortuna is a specialist contract development and manufacturing organisation providing genomic services, custom development and manufacturing support to the IVD, consumer health, life sciences and pharma biotech sectors. The Company is ISO 17025 and ISO 13485 accredited and FDA registered.